News 2013

OBI Pharma Announces NT$ 1.5 Billion Capital Infusion

OBI Pharma, Inc. (GreTai Securities Market: 4174), announced a new round of financing amounting to NT$ 1.5 billion has been completed. This signals the beginning of a new era in …

OBI Pharma Wins the “Greatest Potential Award” at the 2013 Outstanding Biotech Awards

18 July 2013 – ROC President Ma Ying-jeou attended 2013 BIO Taiwan Opening Ceremony and presented the “Company with the Greatest Potential Award” to OBI Pharma (GreTai Securities Market 4174). …

OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.

Taipei, Taiwan – 7 February 2013 – OBI Pharma, Inc. (GreTai Securities Market Code 4174) held its first extraordinary shareholders’ meeting of the year on the morning of 7 February …

OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.

Taipei, Taiwan – 31 January 2013 – A recent paper published by the Academia Sinica explained that a new generation therapeutic cancer vaccine – Globo H-DT (OBI-833) – can effectively …

OBI’s company English name official renamed OBI Pharma, Inc.